Table 1.
Percentage of total IgG-producing immunocytes and anti-tropomyosin isoform 5 (hTM5) IgG-producing immunocytes quantified by ELISPOT assay in the colonic mucosal biopsy specimens in patients with ulcerative colitis (UC), Crohn's colitis (CC) and non-inflammatory bowel disease (non-IBD) controls
| UC (n = 23) | CC (n = 8*) | Non-IBD (n = 10) | ||
|---|---|---|---|---|
| Recto-sigmoid mucosa | ||||
| Percentage of total IgG | ||||
| B cells | Mean ± s.e.m. | 13·2 ± 1·4a | 11·1 ± 1·3b | 6 ± 1c |
| (median, range) | (12, 6–32) | (11, 8–16) | (6, 3–12) | |
| Percentage of anti-hTM5 | ||||
| IgG B cells | Mean ± s.e.m. | 40·1 ± 3·4d | 2·9 ± 1·2e | 4·1 ± 2·1f |
| (median, range) | (42, 8–75) | (2·5, 0–10) | (0, 0–18) | |
| Proximal colon mucosa | ||||
| Percentage of total IgG | ||||
| B cells | Mean ± s.e.m. | 12·6 ± 3·4g | – | – |
| (median, range) | (10, 3–27) | |||
| Percentage of anti-hTM5 | ||||
| IgG B cells | Mean ± s.e.m. | 20·7 ± 6·0h | – | – |
| (median, range) | (17, 0–50) |
*
Biopsy specimens from eight patients included grossly inflamed tissue, five from recto-sigmoid area and three from right colon.
aversusb, no significant difference,aversusc,– P < 0·0002
bversusc, P < 0·008,dversuse or f, P < 0·00001
gversusa, b or c, no significant difference,hversuse, P < 0·02, h versus f, P < 0·03.
dversus h, P < 0·05